Took a starter, interesting play... Will be keeping an eye on it for possible future purchases. Best of luck to everyone.

Yes, sorry to say....

Thank you

My dear friend Pizzabuster 1 passed away early this morning. Words can not express the feeling of loss that his friends and family are experiencing due to the loss of this kind man.


Pizza like all of us had his faults. But underneath it all, he was one of the most sincere and generous and kind-hearted people I have ever had the pleasure to know.

His passing as left a hole in many lives. I look forward to the day when we meet again on the other side of this life.


Rest in Peace my dear friend, you will always be in my thoughts and prayers.

PizzaBuster1 tag line: "God took u to it God will take u through it"

My dear friend Pizzabuster 1 passed away early this morning. Words can not express the feeling of loss that his friends and family are experiencing due to the loss of this kind man.


Pizza like all of us had his faults. But underneath it all, he was one of the most sincere and generous and kind-hearted people I have ever had the pleasure to know.

His passing as left a hole in many lives. I look forward to the day when we meet again on the other side of this life.


Rest in Peace my dear friend, you will always be in my thoughts and prayers.

PizzaBuster1 tag line: "God took u to it God will take u through it"

$FRTD rewards shareholders Fortitude with a special share issuance. S1 to be filed ....

No R/M BS to content with, FRTD shareholders getting a gift.

fed up with all the bullshit! Just trying to keep it real ;)

Board of directors needs to find someone to step up and take this over, throw out all of Karen's bogus crap, sell anything of value and Reverse merge an entity into this company and go forward.

Once new ceo is in place current board needs to be removed as they were complacent during this whole ordeal.

New CEO and New direction is the only chance this has. Anyone know of anyone who would like to be the new CEO, all they need is a real company to place here.

This company is listed as being inactive according to the state of florida, hmmm...

Is this another company Norman Birmingham is looking to snatch up so he can load it with debt from his buddy Rick Papaleo, put a front man in as CEO move the price up a bit and then dilute the hell out of it, while the two hide from the world and use some stooge who will probably deserve the rep he gets for going along with the plan.

Hey z... FRTD is just like:

"Let us not grow weary in doing good, for in due season we shall reap a reward, if we do not lose heart!" Gal. 6:9

FRTD - press on

Strength through Innovation

Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.

Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.

FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.

Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.


Vision Statement
Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.

Mission Statement
Our mission is to set standards of excellence for providing medical devices and services from within our Life Science Division to the healthcare industry. Our company's success, which is characterized by responsiveness and clinical excellence, has been founded on our core principle of dedication and quality care. Physicians, care givers and patients alike can trust FGI's Life Science Division to provide the quality products and services needed to achieve the care they expect and deserve.

Thomas Parilla - Chief Executive Officer:
CEO and Chairman of the Board of Publicly traded Fortitude Group Inc. Mr Parilla is charged with leading Fortitude Group Inc. through its growth stage, and assisting the company in locating and closing quality acquisitions. Providing the company with both growth potential, and the ability to attract proper funding to strengthen its balance sheet.

Mr. Thomas Parilla is a graduate from Mercyhurst University, in Erie, PA having earned his BA Economics. He has 20 years of international and domestic blue chip experience, in both the retail brokerage and investment banking sectors. Mr. Parilla's ties to the university remain close to this day. He currently serves on its Board of Trustees Investment Committee.

He has been featured multiple times in magazines, and also was the economics expert featured on a CBS morning segment entitled "Ask the Experts". Born and raised in the small steel and coal town of Mineral Ridge, Ohio, Mr. Parilla learned the value of a strong work ethic at an early age.

Christopher Cuzzola - President - CEO Life Science Division:
Christopher J. Cuzzola received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Anthony J. Colantonio, MD - Chief Medical Innovation Officer
Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.

Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company's regulatory and quality efforts.

On January 29, 2013 - Fortitude Group Inc., announced the acquisition of Legacy Life Science (L2S)

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

The L2S Comprehensive Airway Management System meets the new ASA Standards.

Fortitudes Group Inc., Life Science Division's Capnography meets the needs of both the practitioner and the patient in all clinical environments by providing the earliest indication of airway obstruction and cessation of breathing. With our products, the caregiver is given instantaneous, continuous results, and is able to intervene at the earliest sign of distress.

Share Structure:
Shares Outstanding- 484,634,404 a/o Jan 24, 2013
Float- 131,915,067 a/o Jan 24, 2013
Authorized Shares- 998,000,000 a/o Jan 23, 2013
Par Value 0.001
Shareholders of Record -267 a/o Jan 24, 2013

STBV- up 30% on news and low volume - she is primed to make a big move !! very low float 1.8 milly....

FRTD - Strength through Innovation

Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.

Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.

FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.

Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.


Vision Statement
Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.

Mission Statement
Our mission is to set standards of excellence for providing medical devices and services from within our Life Science Division to the healthcare industry. Our company's success, which is characterized by responsiveness and clinical excellence, has been founded on our core principle of dedication and quality care. Physicians, care givers and patients alike can trust FGI's Life Science Division to provide the quality products and services needed to achieve the care they expect and deserve.

Thomas Parilla - Chief Executive Officer:
CEO and Chairman of the Board of Publicly traded Fortitude Group Inc. Mr Parilla is charged with leading Fortitude Group Inc. through its growth stage, and assisting the company in locating and closing quality acquisitions. Providing the company with both growth potential, and the ability to attract proper funding to strengthen its balance sheet.

Mr. Thomas Parilla is a graduate from Mercyhurst University, in Erie, PA having earned his BA Economics. He has 20 years of international and domestic blue chip experience, in both the retail brokerage and investment banking sectors. Mr. Parilla's ties to the university remain close to this day. He currently serves on its Board of Trustees Investment Committee.

He has been featured multiple times in magazines, and also was the economics expert featured on a CBS morning segment entitled "Ask the Experts". Born and raised in the small steel and coal town of Mineral Ridge, Ohio, Mr. Parilla learned the value of a strong work ethic at an early age.

Christopher Cuzzola - President - CEO Life Science Division:
Christopher J. Cuzzola received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Anthony J. Colantonio, MD - Chief Medical Innovation Officer
Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.

Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company's regulatory and quality efforts.

On January 29, 2013 - Fortitude Group Inc., announced the acquisition of Legacy Life Science (L2S)

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

The L2S Comprehensive Airway Management System meets the new ASA Standards.

Fortitudes Group Inc., Life Science Division's Capnography meets the needs of both the practitioner and the patient in all clinical environments by providing the earliest indication of airway obstruction and cessation of breathing. With our products, the caregiver is given instantaneous, continuous results, and is able to intervene at the earliest sign of distress.

Share Structure:
Shares Outstanding- 484,634,404 a/o Jan 24, 2013
Float- 131,915,067 a/o Jan 24, 2013
Authorized Shares- 998,000,000 a/o Jan 23, 2013
Par Value 0.001
Shareholders of Record -267 a/o Jan 24, 2013

FRTD- crazy day of trading today... MM'S shook the tree down to 0054 bypassing bids to fill 1 million shares. Closed 0074 on over 3M traded.

I think the company needs to give shareholders some updates on what they have going on, they have been silent, which is not always a bad thing. But peeps need to hear something to keep them motivated..

Peeps need to step up and get off the bid and start hitting the ask on FRTD, otherwise she will never move, liquidity dryin up fast

FRTD- sunrise once again playing games on the ask.. showing 10K took 35K. and he never moved, criminal IMO

Mine as well ! FRTD going to take the 82's, let's see what the MM's are hiding on that ask...

FRTD - looks like peeps are playing this one just right, accumlating all they can under a penny, locking down the float. Hearing rumors of big things coming...

FRTD - Strength through Innovation

Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.

Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.

FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.

Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.


Vision Statement

Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.


Mission Statement

Our mission is to set standards of excellence for providing medical devices and services from within our Life Science Division to the healthcare industry. Our company's success, which is characterized by responsiveness and clinical excellence, has been founded on our core principle of dedication and quality care. Physicians, care givers and patients alike can trust FGI's Life Science Division to provide the quality products and services needed to achieve the care they expect and deserve.

Thomas Parilla - Chief Executive Officer:

CEO and Chairman of the Board of Publicly traded Fortitude Group Inc. Mr Parilla is charged with leading Fortitude Group Inc. through its growth stage, and assisting the company in locating and closing quality acquisitions. Providing the company with both growth potential, and the ability to attract proper funding to strengthen its balance sheet

Mr. Thomas Parilla is a graduate from Mercyhurst University, in Erie, PA having earned his BA Economics. He has 20 years of international and domestic blue chip experience, in both the retail brokerage and investment banking sectors. Mr. Parilla's ties to the university remain close to this day. He currently serves on its Board of Trustees Investment Committee.

He has been featured multiple times in magazines, and also was the economics expert featured on a CBS morning segment entitled "Ask the Experts". Born and raised in the small steel and coal town of Mineral Ridge, Ohio, Mr. Parilla learned the value of a strong work ethic at an early age.



Christopher Cuzzola - President - CEO Life Science Division:

Christopher J. Cuzzola received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Anthony J. Colantonio, MD - Chief Medical Innovation Officer

Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.

Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company's regulatory and quality efforts.



On January 29, 2013 - Fortitude Group Inc., announced the acquisition of Legacy Life Science (L2S)

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

FRTD - Strength through Innovation

Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.

Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.

FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.

Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.


Vision Statement

Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.


Mission Statement

Our mission is to set standards of excellence for providing medical devices and services from within our Life Science Division to the healthcare industry. Our company's success, which is characterized by responsiveness and clinical excellence, has been founded on our core principle of dedication and quality care. Physicians, care givers and patients alike can trust FGI's Life Science Division to provide the quality products and services needed to achieve the care they expect and deserve.

Thomas Parilla - Chief Executive Officer:

CEO and Chairman of the Board of Publicly traded Fortitude Group Inc. Mr Parilla is charged with leading Fortitude Group Inc. through its growth stage, and assisting the company in locating and closing quality acquisitions. Providing the company with both growth potential, and the ability to attract proper funding to strengthen its balance sheet

Mr. Thomas Parilla is a graduate from Mercyhurst University, in Erie, PA having earned his BA Economics. He has 20 years of international and domestic blue chip experience, in both the retail brokerage and investment banking sectors. Mr. Parilla's ties to the university remain close to this day. He currently serves on its Board of Trustees Investment Committee.

He has been featured multiple times in magazines, and also was the economics expert featured on a CBS morning segment entitled "Ask the Experts". Born and raised in the small steel and coal town of Mineral Ridge, Ohio, Mr. Parilla learned the value of a strong work ethic at an early age.



Christopher Cuzzola - President - CEO Life Science Division:

Christopher J. Cuzzola received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Anthony J. Colantonio, MD - Chief Medical Innovation Officer

Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.

Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company's regulatory and quality efforts.



On January 29, 2013 - Fortitude Group Inc., announced the acquisition of Legacy Life Science (L2S)

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

FRTD - Strength through Innovation

Fortitude Group Inc., (FGI) develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.

Fortitude Group Inc., which trades under the ticker symbol FRTD, is a diversified holding company seeking to enhance shareholder value via quality acquisitions, joint ventures and strategic partnerships.

FGI is headquartered in Erie Pennsylvania, in the heart of Erie's technology incubator center. This dynamic company is positioned to capitalize in various diverse market places.

Through its direct holdings, subsidiaries and and/or joint ventures the Fortitude Group Inc. Life Science Division will provide the healthcare market with premium products including innovative medical devices, advanced medical technologies and protocol procedures engineered to prevent the risk of infection in the peri-operative setting and improve clinical healthcare outcomes for patients and providers.


Vision Statement

Fortitude Group Inc., immediate focus is to concentrate in developing our Life Science Division. It is within this division that management strongly believes that shareholder value will be recognized quickly. FGI is committed to provide a suitable return in all our business endeavors that will allow growth and sustainability. The FGI Life Science Division develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company's service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated with (HAC) healthcare acquired conditions with the goal of improving clinical outcomes. With future products, services and medical devices opportunities contained within a pipeline thus positioning the company to achieve a generous percentage of market share from an industry segment that is rapidly expanding.


Mission Statement

Our mission is to set standards of excellence for providing medical devices and services from within our Life Science Division to the healthcare industry. Our company's success, which is characterized by responsiveness and clinical excellence, has been founded on our core principle of dedication and quality care. Physicians, care givers and patients alike can trust FGI's Life Science Division to provide the quality products and services needed to achieve the care they expect and deserve.

Thomas Parilla - Chief Executive Officer:

CEO and Chairman of the Board of Publicly traded Fortitude Group Inc. Mr Parilla is charged with leading Fortitude Group Inc. through its growth stage, and assisting the company in locating and closing quality acquisitions. Providing the company with both growth potential, and the ability to attract proper funding to strengthen its balance sheet

Mr. Thomas Parilla is a graduate from Mercyhurst University, in Erie, PA having earned his BA Economics. He has 20 years of international and domestic blue chip experience, in both the retail brokerage and investment banking sectors. Mr. Parilla's ties to the university remain close to this day. He currently serves on its Board of Trustees Investment Committee.

He has been featured multiple times in magazines, and also was the economics expert featured on a CBS morning segment entitled "Ask the Experts". Born and raised in the small steel and coal town of Mineral Ridge, Ohio, Mr. Parilla learned the value of a strong work ethic at an early age.



Christopher Cuzzola - President - CEO Life Science Division:

Christopher J. Cuzzola received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Anthony J. Colantonio, MD - Chief Medical Innovation Officer

Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management.

Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company's regulatory and quality efforts.



On January 29, 2013 - Fortitude Group Inc., announced the acquisition of Legacy Life Science (L2S)

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

FRTD 79 down - 008 next to fall...

FRTD my buddy taking 100K down at the 008!!, go long ...

FRTD, I am throwing pebbles at it, need someone with a rock to break this out added another 15K shares at 0.0077...

I know your loaded as well z, hoping someone will hear my cry for assistance. LOL

Oh yeah, good afternoon to you sir !

FRTD took another 14K shares at 77, running out of ammo, looking for help to push this into a strong close 009 or better. L2 is looking thin

FRTD - L2 looking thin added some 77's...

I'm tapping that 77 the best I can, FRTD going long and strong on this one

Afternoon AC.. there was a great post placed on FRTD IMO.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86174117

Hey z... excellent post over on the FRTD board...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=86174117

Hoss Why I think FRTD should be part of your investment strategy.

Fortitude Group Inc. is now under the direction of Thomas Parilla. This once beaten and battered shell finally has a CEO and management team that is up to the task of building a real viable company. FRTD recently acquired Legacy Life Science (L2S).

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

The company is best described as:

Fortitude Group Inc. develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company’s service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.



--------------------------------------------------------------------------------


FRTD as you will soon realize is not your typical penny stock. Just look at the bio’s of the company’s management team:

Thomas Parilla - CEO

VP Regional Manager of Brokerage operations for NW Pennsylvania

1st National Bank Investments

December 1999 – December 2002 (3 years 1 month)



VP Regional Manager of all Brokerage Operations in NW PA.

Honors & Awards

National City Bank Chairman's Conference Award

National City Bank

1998

Highest Brokerage Award at National City Bank

Chairman's Conference Award at First National Bank

2000

Highest Brokerage Award at First National Bank

3 Time Winner of the Putnam Funds Golden Scale Council

Putnam Funds

Highest Award for Sales and Client Service from Putnam Mutual Funds

3 Time Winner of the American Funds - All American Team

American Funds

Highest Award for Sales and Client service by The American Funds

Federated Funds - President's Achievement Club

Federated Funds

Highest Award for Sales and Client Service by Federated Funds

Van Kampen Funds - Generations of Experience Club

Van Kampen Funds

Highest award for Sales and Client Service by The Van Kampen Funds

National City Bank - Rookie of the Year Award

National City Bank

Awarded as the top 1st year Broker in the Northwest Pennsylvania Region

Christopher J. Cuzzola President - received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Dr. Anthony J Colantonio - Chief Technology Officer - Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management. Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As a clinician-inventor, Colantonio is a tireless advocate for patients and medical providers and has dedicated his entrepreneurial career to identifying critical healthcare problems and solving them with innovative products and services. Anthony holds two utility patents through the USPTO and six patents pending. As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company’s regulatory and quality efforts. Dr. Colantonio plays a critical role in the development of professional partnerships with leading healthcare institutions, and key opinion leaders in the fields of anesthesia, interventional pain management, and infection prevention services with specific emphasis upon the reduction of healthcare acquired conditions (HACs). "

Given the sad history of this shell prior to the new management and the new field of endeavor undertaken, it is understandable that some may be hesitant to take a position. But while some sit on the sidelines, others are accumulating all they can of this dynamic company, while the PPS is still cheap.

It is true that the new CEO has his work cut out for him, giving the past mismanagement and uncaring displayed towards shareholders, as one convertible after another has pounded this stock under the old management. That has all changed, the printing press has stopped. And as new investors step up it is plain to see that the flow of stock being sold into the market has slowed. Once this company starts releasing expected news, the PPS will rise.

Now would be a good time for you to take one more good look at FRTD.

Thank you chazaq...

Why I think FRTD should be part of your investment strategy.

Fortitude Group Inc. is now under the direction of Thomas Parilla. This once beaten and battered shell finally has a CEO and management team that is up to the task of building a real viable company. FRTD recently acquired Legacy Life Science (L2S).

The L2S premium product portfolio contains the Comprehensive Airway Management System consisting of five, patented FDA approved products ready for worldwide distribution and sales. The Comprehensive Airway Management System is engineered to significantly reduce and prevent respiratory distress in the perioperative procedural sedation environment (anesthesia). A common scenario in peri-operative procedural sedation involves degradation of patient airway monitoring and management; and therefore, constitutes the designation as a Hospital Acquired Condition or (HAC) for respiratory related distress.

The company is best described as:

Fortitude Group Inc. develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company’s service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.



--------------------------------------------------------------------------------


FRTD as you will soon realize is not your typical penny stock. Just look at the bio’s of the company’s management team:

Thomas Parilla - CEO

VP Regional Manager of Brokerage operations for NW Pennsylvania

1st National Bank Investments

December 1999 – December 2002 (3 years 1 month)



VP Regional Manager of all Brokerage Operations in NW PA.

Honors & Awards

National City Bank Chairman's Conference Award

National City Bank

1998

Highest Brokerage Award at National City Bank

Chairman's Conference Award at First National Bank

2000

Highest Brokerage Award at First National Bank

3 Time Winner of the Putnam Funds Golden Scale Council

Putnam Funds

Highest Award for Sales and Client Service from Putnam Mutual Funds

3 Time Winner of the American Funds - All American Team

American Funds

Highest Award for Sales and Client service by The American Funds

Federated Funds - President's Achievement Club

Federated Funds

Highest Award for Sales and Client Service by Federated Funds

Van Kampen Funds - Generations of Experience Club

Van Kampen Funds

Highest award for Sales and Client Service by The Van Kampen Funds

National City Bank - Rookie of the Year Award

National City Bank

Awarded as the top 1st year Broker in the Northwest Pennsylvania Region

Christopher J. Cuzzola President - received a M.Ed. in Administrative Leadership, Learning Theory, and Design from Edinboro University and a B.A. from Mercyhurst University. Cuzzola brings a history of exceptional performance applying his entrepreneurial skills to the challenging life science medical device industry.

During his career with Pfizer, Chris was a consistent high achiever while earning several top specialty and hospital sales performance awards, including a number one ranking as national sales representative of the year. Cuzzola has extensive training in various disease states including infectious diseases. In addition to family and professional passions, Chris remains dedicated to causes associated with advancing education and research.

Dr. Anthony J Colantonio - Chief Technology Officer - Dr. Colantonio completed fellowship training in Interventional Pain Medicine at the Oregon Health and Science University, residency training at Duke University in Anesthesiology, and medical and undergraduate education at Georgetown University and is a Diplomat of the American Board of Anesthesiology and the American Academy of Pain Management. Dr. Colantonio is the Director of the Clinic for Specialty Pain Services at Meadville Medical Center, with a clinical focus upon neuromodulation therapy and geriatric care. Dr. Colantonio is a regional key opinion leader for numerous pharmaceutical and medical device companies and a national speaker for Pfizer Pharmaceuticals.

As a clinician-inventor, Colantonio is a tireless advocate for patients and medical providers and has dedicated his entrepreneurial career to identifying critical healthcare problems and solving them with innovative products and services. Anthony holds two utility patents through the USPTO and six patents pending. As the Chief Medical Officer of the Life Science Division, Dr. Colantonio leads the research and development efforts from initial product design to bench-top testing, clinical trials, and final product validation through the company’s regulatory and quality efforts. Dr. Colantonio plays a critical role in the development of professional partnerships with leading healthcare institutions, and key opinion leaders in the fields of anesthesia, interventional pain management, and infection prevention services with specific emphasis upon the reduction of healthcare acquired conditions (HACs). "

Given the sad history of this shell prior to the new management and the new field of endeavor undertaken, it is understandable that some may be hesitant to take a position. But while some sit on the sidelines, others are accumulating all they can of this dynamic company, while the PPS is still cheap.

It is true that the new CEO has his work cut out for him, giving the past mismanagement and uncaring displayed towards shareholders, as one convertible after another has pounded this stock under the old management. That has all changed, the printing press has stopped. And as new investors step up it is plain to see that the flow of stock being sold into the market has slowed. Once this company starts releasing expected news, the PPS will rise.

Now would be a good time for you to take one more good look at FRTD.

Thanks LB, I have been hovering around the board waiting until I thought I had something of substance to post.

GLTY - GLTA !!

FRTD - new management working to clean up this once beaten and battered shell. Prior management never cared about shareholders or building a business.

I have faith in the new team, and the FDA approved product. Chart displaying a Golden Cross.

Marked the board...

FRTD - chart is looking good - Golden Cross.

Wishing you a happy easter as well z...

Afternoon z...

FRTD cycling, still not enough volume to break her out. I guess we are eating through the remainder of whatever convertible was put into place by past management. I would also guess that trades who bought down in the 002 to 004 range are getting out as well,

All we have to do is keep soaking up shares, when inventory dries up watch out....

Thanks for the reply, good to know . FRTD is really getting primed, won't be to much longer before she goes IMO.

GLTY - GO FRTD !!!

a little bit of a shake today = FRTD clearing out weaker hands and locking the float down..

Besides the ask slapping going on, could use better bid support !!

FRTD - Golden Cross !

http://scharts.co/ZTSje3

Fortitude Group Inc. develops practical solutions for healthcare with direct holdings, subsidiaries and or joint ventures. The Company’s service-product portfolio includes premium FDA approved medical devices and advanced technologies engineered to prevent the risk associated healthcare acquired conditions and improve clinical outcomes.